ASCO: AstraZeneca's hat trick, and palliative care's spotlight

"Arrestingcancer."ADAMFEUERSTEIN/STATYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAme AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli




comprehensive

author：explore    Page View：64523
Alastair Grant/AP

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

advertisement

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： AI can decode, harness the power of the humane immune system
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures